scholarly article | Q13442814 |
P50 | author | Daniela Pietra | Q42033215 |
Francesco Passamonti | Q42389421 | ||
Robert Kralovics | Q29887665 | ||
Ashot Harutyunyan | Q42033212 | ||
P2093 | author name string | M Cazzola | |
T Berg | |||
R Jäger | |||
B Gisslinger | |||
H Gisslinger | |||
E Rumi | |||
T Klampfl | |||
D Olcaydu | |||
P2860 | cites work | Taxing sugar-sweetened beverages | Q43180928 |
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Q44008600 | ||
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders | Q46913469 | ||
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms | Q47960630 | ||
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. | Q50721189 | ||
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. | Q51761197 | ||
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. | Q51768323 | ||
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. | Q51806902 | ||
Ikaros is critical for B cell differentiation and function. | Q52123185 | ||
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. | Q54511975 | ||
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros | Q57734316 | ||
A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma | Q71806450 | ||
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases | Q80607021 | ||
Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms | Q95779600 | ||
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis | Q24609999 | ||
Recurring mutations found by sequencing an acute myeloid leukemia genome | Q24634204 | ||
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report | Q27851487 | ||
Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment | Q28202932 | ||
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2 | Q28243103 | ||
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia | Q28253771 | ||
Multiple hematopoietic defects and delayed globin switching in Ikaros null mice | Q28510404 | ||
The Ikaros gene is required for the development of all lymphoid lineages | Q28594316 | ||
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen | Q29615061 | ||
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo | Q29616612 | ||
A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
Mutation in TET2 in myeloid cancers | Q29619292 | ||
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias | Q34162729 | ||
Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation | Q34412659 | ||
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 | ||
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model | Q35849213 | ||
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia | Q36185370 | ||
The myeloproliferative disorders | Q36675917 | ||
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia | Q37172988 | ||
JAK mutations in high-risk childhood acute lymphoblastic leukemia | Q37224111 | ||
Genetic complexity of myeloproliferative neoplasms. | Q37255024 | ||
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance | Q38440701 | ||
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute | Q39826912 | ||
Ikaros dominant negative isoform (Ik6) induces IL-3-independent survival of murine pro-B lymphocytes by activating JAK-STAT and up-regulating Bcl-xl levels | Q39984463 | ||
P433 | issue | 7 | |
P304 | page(s) | 1290-1298 | |
P577 | publication date | 2010-05-27 | |
P1433 | published in | Leukemia | Q6534498 |
P1476 | title | Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. | |
P478 | volume | 24 |
Q36858928 | A de novo acute myeloid leukemia (AML-M4) case with a complex karyotype and yet unreported breakpoints |
Q43010395 | A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells. |
Q42583748 | Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. |
Q36147014 | Alternative Splice Variants Modulates Dominant-Negative Function of Helios in T-Cell Leukemia |
Q34233335 | An adult B-cell precursor acute lymphoblastic leukemia with multiple secondary cytogenetic aberrations |
Q34166859 | Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management |
Q33558154 | Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase |
Q92915669 | Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design |
Q38050656 | B-lineage transcription factors and cooperating gene lesions required for leukemia development |
Q38014534 | BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques |
Q26777265 | Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors |
Q39399799 | CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2. |
Q36964853 | CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation |
Q43405916 | Clinical significance of genetic aberrations in secondary acute myeloid leukemia |
Q55030822 | Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation. |
Q34302770 | Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms |
Q39144353 | Direct protein interactions are responsible for Ikaros-GATA and Ikaros-Cdk9 cooperativeness in hematopoietic cells |
Q43112746 | Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression |
Q33413428 | Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients |
Q38999178 | Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts |
Q51250068 | Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma. |
Q42183250 | EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations |
Q36001930 | Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies |
Q38329285 | Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. |
Q35995222 | Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome |
Q38066786 | Genetic and epigenetic alterations of myeloproliferative disorders |
Q38159973 | Genetic basis of MPN: Beyond JAK2-V617F. |
Q26823651 | Genetics of myeloproliferative neoplasms |
Q41932257 | Haploinsufficiency of Tumor Suppressor Genes is Driven by the Cumulative Effect of microRNAs, microRNA Binding Site Polymorphisms and microRNA Polymorphisms: An In silico Approach |
Q35835653 | IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F |
Q42415934 | IDH1 and IDH2 mutations in myeloid neoplasms - Novel paradigms and clinical implications |
Q34348505 | Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing |
Q38371003 | Ikaros and leukaemia |
Q36730409 | Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling |
Q53240971 | Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation. |
Q42057738 | Ikaros: master of hematopoiesis, agent of leukemia |
Q57465846 | Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene |
Q38127417 | Inherited predisposition to myeloproliferative neoplasms |
Q34786517 | Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma |
Q34150008 | JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations |
Q36612537 | JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. |
Q38044736 | JAK2 inhibitors in the treatment of myeloproliferative neoplasms. |
Q37833893 | Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond |
Q38050756 | Molecular biology of Philadelphia-negative myeloproliferative neoplasms |
Q54574818 | Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? |
Q50072000 | Mutations in myeloproliferative neoplasms - their significance and clinical use. |
Q40298579 | Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium |
Q37877727 | Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? |
Q34629928 | Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies |
Q37869152 | New JAK2 inhibitors for myeloproliferative neoplasms |
Q36909019 | Normal and malignant megakaryopoiesis |
Q49978793 | Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms |
Q38926804 | Prognosis of Primary Myelofibrosis in the Genomic Era |
Q40727272 | Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients |
Q36709009 | Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia |
Q35103926 | Regulator of myeloid differentiation and function: The secret life of Ikaros |
Q83141302 | Role of TET2 mutations in myeloproliferative neoplasms |
Q38100790 | Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians |
Q33393587 | Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis |
Q38683077 | The evolution and clinical relevance of prognostic classification systems in myelofibrosis |
Q53703572 | The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. |
Q33850043 | The transcription factor Ikaros inhibits cell proliferation by downregulating ANXA4 expression in hepatocellular carcinoma |
Q36594686 | Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia |
Q37968531 | Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? |
Q42870230 | Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology |